BARBARA REED: Open Payments
NPI 1083864268 · SOUTHLAKE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,742 in 80 payments from 14 companies in 2025. Trend: 2023 $1,819 · 2024 $1,846 · 2025 $2,742
Food & beverage: $2,742
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $548 |
| Axsome Therapeutics, Inc. | 9 | $476 |
| Otsuka America Pharmaceutical, Inc. | 14 | $320 |
| E.R. Squibb & Sons, L.L.C. | 10 | $230 |
| Teva Pharmaceuticals USA, Inc. | 5 | $204 |
| Supernus Pharmaceuticals, Inc. | 4 | $180 |
| Alkermes, Inc. | 4 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $152 |
| Neurocrine BioSciences, Inc. | 5 | $122 |
| Vanda Pharmaceuticals Inc. | 1 | $117 |
Products named: CAPLYTA, Auvelity, REXULTI, COBENFY, Qelbree, TRINTELLIX, AUSTEDO XR, LYBALVI.
Industry payments across TX — which companies pay providers there.
